Novo Holdings completes $16.5 bln takeover of Catalent

Reuters2024-12-18

Novo Holdings completes $16.5 bln takeover of <a href="https://laohu8.com/S/CTLT">Catalent</a>

Dec 18 (Reuters) - Novo Holdings has completed its $16.5 billion takeover of Catalent CTLT.N, the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled.

Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk NOVOb.CO, which makes the blockbuster GLP-1 injectable weight-loss drug Wegovy.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Maju Samuel)

((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492186252?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-18 22:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492186252","market":"us","top_or_hot":-1,"title":"Novo Holdings completes $16.5 bln takeover of Catalent","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Novo Holdings completes $16.5 bln takeover of <a href=\"https://laohu8.com/S/CTLT\">Catalent</a> </title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span>Novo Holdings has completed its $16.5 billion takeover of Catalent <span>CTLT.N</span>, the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled. </p><p>Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk <span>NOVOb<a href=\"https://laohu8.com/S/02403\">.C</a>O</span>, which makes the blockbuster GLP-1 injectable weight-loss drug Wegovy.</p><p> (Reporting by Bhanvi Satija in Bengaluru; Editing by Maju Samuel)</p><p> ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Holdings completes $16.5 bln takeover of Catalent</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Holdings completes $16.5 bln takeover of Catalent\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-18 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nL4N3NJ10C:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Holdings completes $16.5 bln takeover of Catalent Dec 18 (Reuters) - Novo Holdings has completed its $16.5 billion takeover of Catalent CTLT.N, the contract drug manufacturer announced on ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nL4N3NJ10C:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nL4N3NJ10C:1","article_id":"2492186252","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492186252","pubTimestamp":1734530693,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Novo Holdings completes $16.5 bln takeover of Catalent Dec 18  - Novo Holdings has completed its $16.5 billion takeover of Catalent CTLT.N, the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled. Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk NOVOb.CO, which makes the blockbuster GLP-1 injectable weight-loss drug Wegovy.  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"Novo Holdings完成165亿美元收购Catalent","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTLT":0.9},"content_text":"Novo Holdings completes $16.5 bln takeover of Catalent Dec 18 (Reuters) - Novo Holdings has completed its $16.5 billion takeover of Catalent CTLT.N, the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled. Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk NOVOb.CO, which makes the blockbuster GLP-1 injectable weight-loss drug Wegovy. (Reporting by Bhanvi Satija in Bengaluru; Editing by Maju Samuel) ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"shareholding,corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492186252"}